Quanterix FY Conference Summary Company Overview - **Company**: Quanterix (NasdaqGM: QTRX) - **Industry**: Life Sciences Tools and Diagnostics - **Key Management**: Everett Cunningham (CEO), Vandana Sriram (CFO) Core Points and Arguments Leadership Transition - Everett Cunningham, with over 30 years in healthcare, joined Quanterix from Illumina, attracted by the need for breakthrough technologies in neurology, oncology, and immunology [6][7] - Emphasized the solid base business in research tools and the potential for growth in diagnostics, particularly in Alzheimer's [7][8] Financial Health - Quanterix has a strong balance sheet with $100 million in cash and no debt [8] - The company aims to achieve breakeven cash flow in the second half of the year and has set a synergy target of $84 million from the Akoya acquisition by the end of Q1 [8] Growth Strategy - Projected growth for 2026 is between 0%-3%, with a focus on prioritizing next-generation platforms and technologies [14][16] - Plans to build a comprehensive diagnostics strategy, including reimbursement strategies and clinical utility studies, with results expected mid-year [18][19] Performance Insights - The fourth quarter showed a significant improvement, with consumables driving growth and a recurring revenue profile now at 75% [21][22] - The company is seeing a reduction in cash burn, down to approximately $3 million from previous levels of $15 million-$20 million [22] Akoya Acquisition - The acquisition has diversified Quanterix's business from 90% neurology to 60% neurology and 40% oncology/immunology, enhancing the company's market position [23][24] - Early integration efforts have been positive, with a unified company culture emerging [25][26] Market Position and Future Outlook - The company anticipates a return to high single-digit growth rates in a normalized market, driven by consumables and diagnostic partnerships [29][36] - The focus will be on optimizing technology and expanding the Accelerator Laboratory's role in generating insights for next-gen assay development [46][47] Alzheimer's Diagnostics - Quanterix is working on a multi-analyte blood test for Alzheimer's, with a 510(k) submission made in January and results expected in 6-9 months [66][73] - The company aims to establish an end-to-end strategy for diagnostics, leveraging its CLIA lab capabilities [95][96] Competitive Landscape - Quanterix's LucentAD test is positioned as a unique offering with high sensitivity and specificity, differentiating it from competitors [103][104] - The company welcomes competition as it indicates market attractiveness and is committed to maintaining a strong commercial approach [121][123] Additional Important Insights - The Accelerator Laboratory serves as a leading indicator for customer interests and next-gen assay development [46][47] - The company is expanding its infrastructure outside the U.S., particularly in markets with aging populations like China and Korea [116] - Future growth opportunities are anticipated from service offerings similar to those in the Accelerator Laboratory [65] This summary encapsulates the key points discussed during the Quanterix FY Conference, highlighting the company's strategic direction, financial health, and market positioning within the life sciences tools and diagnostics industry.

Core Insights - 10x Genomics, Inc. announced preliminary, unaudited financial results for Q4 and full year 2025, highlighting both growth and challenges in revenue streams [1][6]. Financial Results Summary Fourth Quarter 2025 - Revenue for Q4 2025 was approximately $166.0 million, reflecting an 11% sequential growth and a 1% increase year-over-year [6]. - Instruments revenue was about $15.5 million, showing a 29% sequential growth but a 36% decrease compared to the same period last year [6]. - Consumables revenue reached approximately $141.7 million, with an 11% sequential growth and a 6% increase year-over-year [6]. - Services and License and Royalty revenue was approximately $8.8 million, representing a 3% decrease sequentially but a 23% growth year-over-year [6]. Full Year 2025 - Total revenue for the year ended December 31, 2025, was approximately $642.8 million, with a 2% decrease from the prior year when excluding $44.1 million related to patent litigation settlements [6]. - Instruments revenue for the full year was approximately $56.8 million, a 39% decrease from the previous year [6]. - Consumables revenue for the year was approximately $507.2 million, reflecting a 3% growth over the prior year [6]. - Services and License and Royalty revenue was approximately $34.8 million, representing a 41% growth year-over-year when excluding the patent litigation settlements [6]. Operational Highlights - Cumulative sales of Chromium instruments exceeded 6,400, while cumulative Spatial instruments sold surpassed 1,500 by the end of 2025 [6]. - Single Cell consumables reactions sold increased by more than 20% compared to the prior year [6]. - Cash, cash equivalents, and marketable securities totaled approximately $520 million as of December 31, 2025 [6]. Management Commentary - The CEO of 10x Genomics expressed pride in the team's resilience and innovation throughout 2025, emphasizing strengthened customer partnerships and operational discipline [4].

Core Insights - The Brown Capital Management Small Company Fund experienced an 8.59% return in Q2 2025, underperforming the Russell 2000® Growth index which returned 11.97% [1] - The underperformance was noted to occur in the last few weeks of the quarter [1] Company Highlights - Bio-Techne Corporation (NASDAQ:TECH) is highlighted in the investor letter, with a market capitalization of $7.973 billion [2] - Bio-Techne's one-month return was -3.81%, and it experienced a significant decline of 31.43% over the past 52 weeks, closing at $51.26 per share on September 12, 2025 [2] - Bio-Techne Corporation was identified as a detractor to the fund's performance in Q2 2025 [3]

Financial Data and Key Metrics Changes - The company reported a strong top-line growth of 6% core revenue, with significant contributions from pharma and CAM segments [4][8] - The guidance for revenue was raised by 25%, driven by broad-based growth, particularly in pharma and CDMO [4][6] - Gross margins were impacted by tariffs, leading to a 200 basis point decline year-on-year, with expectations for sequential improvement in the fourth quarter [12][14][17] Business Line Data and Key Metrics Changes - Pharma QAQC grew mid-teens in Europe, driven by consolidation of supply chains and new capabilities [6][30] - The CDMO segment experienced a remarkable 20% growth, with bookings extending into 2026 [8][37] - The CAM segment also saw 10% growth in both chemicals and advanced materials, supported by a strong installed base and new investments [44][45] Market Data and Key Metrics Changes - The A and G segment showed stability with mid- to high single-digit growth in Europe and 20% growth in China, although the U.S. market faced challenges [26][27] - In China, the pharma and biopharma sectors are experiencing high innovation rates, with significant out-licensing activity [49][50] - The overall market for PFAS testing is estimated to be around $500 million, with the company growing 50% year-over-year globally [71][75] Company Strategy and Development Direction - The company is focused on innovation and productivity improvements, particularly in the CDMO and pharma segments, which are expected to drive growth in the coming years [31][84] - There is a strong emphasis on maintaining close relationships with customers and enhancing service offerings, particularly in China [62][63] - The company is disciplined in M&A activities, looking for high-quality targets that align with its strategic goals [80][81] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in a gradual improvement in the operating environment, despite geopolitical uncertainties and tariff impacts [19][78] - The company anticipates a strong fourth quarter and is optimistic about mid-single-digit growth for the next year, while remaining cautious due to potential external shocks [78][79] - The management highlighted the importance of the Ignite program in driving cost efficiencies and enhancing value creation [85] Other Important Information - The company has seen a shift in customer decision-making processes, with site managers now approving CapEx budgets, indicating a positive trend in capital spending [34] - The BioVectra acquisition is performing well, with expected synergies contributing positively to growth [41][42] Q&A Session Summary Question: What is the outlook for the fourth quarter and next year? - Management raised the implied fourth quarter organic revenue guidance to $5 million to $6 million, indicating optimism for continued growth [76][78] Question: How is the company addressing tariff impacts? - The company expects tariffs to remain high in the fourth quarter but anticipates a reduction in tariff costs by 2026, which will become a tailwind for the business [14][19] Question: What is the status of the PFAS market? - The PFAS market is expected to recover after a temporary slowdown due to regulatory changes, with long-term growth drivers remaining strong [71][73]

Core Insights - Seer, Inc. has appointed Isaac Ro to its Board of Directors, enhancing its leadership team with expertise in financial leadership and life sciences [1][2] Company Overview - Seer, Inc. specializes in deep, unbiased proteomics, providing insights with scale, speed, precision, and reproducibility [4] - The company’s Proteograph Product Suite integrates engineered nanoparticles, automation instrumentation, consumables, and analytical software to address challenges faced by traditional proteomic technologies [4] Leadership and Experience - Isaac Ro is a Partner at Catalio Capital Management, with a history of leading investments in life science companies and serving on various boards [2] - Ro has previously held significant roles, including Executive Chairman of Haystack Oncology and Chief Financial Officer at Sema4 and Thrive Earlier Detection, guiding these companies through key transitions and acquisitions [2]

Core Insights - The article emphasizes the importance of efficiency levels in assessing a company's potential for profitability, suggesting that higher efficiency correlates with better price performance [1] Efficiency Ratios - Receivables Turnover: This ratio measures a company's ability to collect debts and extend credit, with a higher ratio indicating better performance [2] - Asset Utilization: This ratio reflects a company's efficiency in converting assets into sales, with higher values suggesting better efficiency [3] - Inventory Turnover: This ratio indicates how well a company manages its inventory relative to its cost of goods sold, with higher values signaling effective inventory management [4] - Operating Margin: This ratio assesses a company's control over operating expenses, with higher values indicating more efficient expense management [5] Screening Criteria - The screening process included a favorable Zacks Rank (1 Strong Buy) alongside the efficiency ratios, narrowing down over 7,906 stocks to 15 strong candidates [6][9] Top Stocks Identified - The top five stocks identified for their efficiency include: - Tsakos Energy Navigation Limited (TEN) with an average four-quarter earnings surprise of 46.7% [10] - 10x Genomics, Inc. (TXG) also with an average four-quarter earnings surprise of 46.7% [11] - Pan American Silver Corp. (PAAS) with an average four-quarter earnings surprise of 45.2% [12] - Wolverine World Wide, Inc. (WWW) with an average four-quarter earnings surprise of 39.1% [13] - Interface (TILE) with an average four-quarter earnings surprise of 33.5% [14]

Financial Data and Key Metrics Changes - The company reported sales of $771 million, reflecting a 9% increase as reported and an 8% increase in constant currency compared to the previous year [16] - Non-GAAP earnings per share (EPS) were $2.95, up 12% year on year, while GAAP EPS was $2.47 [19] - Gross margin for the quarter was 58.3%, and adjusted operating margin was 29.1%, impacted by regional sales mix and tariff surcharges [20] Business Line Data and Key Metrics Changes - Instruments grew in mid-single digits, led by high single-digit growth in the liquid chromatography (LC) and mass spectrometry (MS) portfolio [7] - Recurring revenue grew 11%, driven by 9% service growth and double-digit chemistry growth [8] - Chemistry benefited from approximately $8 million in sales pull forward related to tariff dynamics, with overall constant currency growth rate at 7% and chemistry up 10% [10] Market Data and Key Metrics Changes - By end market, pharma grew low double digits, industrial grew 6%, and academic and government declined low single digits [9][16] - In the Americas, growth was partially offset by weakness in the TA division, particularly in macro-sensitive polymer and materials testing applications [8] - Asia grew 14%, driven by double-digit growth in China, India, and Japan, while Europe grew 8% [18] Company Strategy and Development Direction - The company is focused on three strategic pillars: commercial execution, revitalizing innovation, and capturing long-term growth in high-growth adjacencies [11] - The pending combination with BD's biosciences and diagnostic solutions business is expected to accelerate entry into high-growth adjacencies and enhance the company's growth trajectory [26] - The company raised its full-year 2025 constant currency sales growth guidance to 5.5% to 7.5% and adjusted EPS guidance to $12.95 to $13.05 [15][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong momentum of the core business and the positive impact of the upcoming combination with BD [26] - The company anticipates a gradual return to growth for BD's biosciences and diagnostics solutions business, with expected growth rates of 4.5% in 2026 and 5% in 2027 [31] - Management acknowledged ongoing industry headwinds in pharma drug discovery and academic funding but remains optimistic about the overall growth potential [30][97] Other Important Information - The company plans to use free cash flow to pay down $100 million of debt and increase cash reserves in the second half of the year [22] - The company expects to deliver $345 million in adjusted EBITDA synergies from the combination with BD by year five, with $200 million in cost synergies and $290 million in revenue synergies [33][37] Q&A Session Summary Question: Can you provide an update on the replacement cycle in LC and competitive dynamics? - Management noted that the LCMS segment continues to grow high single digits, with strong replacement activity among large pharma customers and increasing growth in the CDMO customer base [55] Question: What is the timeline for bringing new products to market in microbiology? - Management indicated that it would take approximately three to five years to fully realize the opportunities in microbiology, with potential product introductions in two to three years [61] Question: How do you expect the margin to evolve in the fourth quarter? - Management expects progressive improvement in margins as volume leverage kicks in, with specific impacts from geographical mix and tariff remediation costs [80] Question: Can you elaborate on the $8 million sales pull forward? - Management expressed confidence in the $8 million figure based on order patterns and discussions with customers, indicating it may impact both Q3 and Q4 [84] Question: What is the outlook for the drug discovery business? - Management stated that the drug discovery segment remains slow, with no significant changes expected in the replacement cycle for this area [97]

Financial Data and Key Metrics Changes - The company reported adjusted EPS of $0.56 for Q3, up from $0.48 in the prior year, while GAAP EPS was $0.14 compared to $0.31 last year [20] - Q3 revenue reached $316.2 million, reflecting a 6% organic growth year over year and a 4% reported growth [20] - Adjusted gross margin was 71.6%, slightly down from 71.9% last year, while adjusted operating margin improved to 34.9%, up 190 basis points from the prior year [22] Business Line Data and Key Metrics Changes - The Protein Sciences segment achieved reported sales of $227.7 million, with organic revenue growth of 7% [25] - The Diagnostics and Spatial Biology segment reported sales of $89.2 million, with both reported and organic growth at 2% [26] - The GMP reagents business saw trailing twelve-month growth of over 13%, while the cell and gene therapy product line had a trailing twelve-month growth rate of over 30% [12][79] Market Data and Key Metrics Changes - North America experienced low single-digit growth, driven primarily by pharma customers, while Europe saw mid single-digit growth led by academic customers [21] - China faced a mid single-digit decline due to challenging economic conditions, but the rest of Asia increased mid-teens [21] - The academic market in the U.S. was flat, impacted by NIH funding uncertainties, while the diagnostics reagents division showed year-to-date growth in the high single digits [15][21] Company Strategy and Development Direction - The company is focused on balancing investments for future growth while driving operational efficiencies, maintaining industry-leading profitability [5] - The FDA's recent emphasis on reducing animal testing is seen as an opportunity for the company's organoid solutions, which are expected to accelerate growth [11] - The company is actively managing tariff impacts through optimization of its global footprint and supply chain adjustments [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating uncertainties related to NIH funding and tariffs, noting that past experiences suggest severe cuts to NIH funding are unlikely [28][66] - The company anticipates a temporary slowdown in growth momentum to low single digits in Q4 due to macro uncertainties [31] - Management remains optimistic about long-term growth prospects, emphasizing the alignment of their product portfolio with NIH research priorities [9][66] Other Important Information - The company returned $12.6 million in dividends and $100 million through stock buybacks during Q3, with a new share repurchase program authorized for up to $500 million [24] - The balance sheet remains strong with $140.7 million in cash and a total leverage ratio well below one times EBITDA [24] Q&A Session Summary Question: Impact of NIH funding uncertainties on guidance - Management indicated that while NIH funding uncertainties are a concern, they believe the impact on long-term growth will be immaterial, as historical trends show Congress often increases NIH budgets despite proposed cuts [66][68] Question: Clarification on pharma growth rates - Management clarified that pharma experienced double-digit growth in Q3, but they expect a step down in organic growth in Q4 due to tariff impacts and academic market slowdowns [36][38] Question: Local manufacturing footprint in China - Management confirmed that tariffs have not changed their strategy for local manufacturing in China, which is seen as beneficial for minimizing cross-border tariff impacts [51] Question: Expectations for fiscal year 2026 - Management stated that they will provide a soft guide for fiscal year 2026 in three months, anticipating more clarity on headwinds affecting end markets [42][63] Question: Biotech customer spending trends - Management noted that biotech funding is sensitive to capital markets, leading to more frugal spending, which was reflected in flat growth for biotech customers in Q3 [88]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenues of $57 million, aligning with expectations, and full year revenues of $259 million, near the midpoint of the previously stated range of $255 million to $265 million [12][13] - GAAP net loss before non-controlling interests was $46 million for Q4 2024, compared to a loss of $110 million in Q4 2023, while the full year net loss was $260 million, up from $138 million in 2023 [15][16] - Adjusted EBITDA for Q4 2024 was a negative $1 million, down from $21 million in Q4 2023, with full year adjusted EBITDA at $36 million, reflecting a margin of 14% [15][17] Business Line Data and Key Metrics Changes - The biologic safety testing segment generated $15 million in Q4 and $63 million for the full year, with an adjusted EBITDA margin of about 70% [12][24] - The nucleic acid production segment had revenues of $42 million in Q4, including $14 million from high-volume CleanCap, and full year revenues of $196 million with an adjusted EBITDA margin of 26% [13][23] Market Data and Key Metrics Changes - Revenue breakdown by customer type for 2024 showed 48% from biopharma, 25% from life science and diagnostics, and 18% through distributors [14] - The company reported $13.6 million in revenue from China for the full year, with expectations for flat growth in 2025 [98][100] Company Strategy and Development Direction - The company is focused on returning its base business to growth, projecting revenues of $185 million to $205 million for 2025, excluding high-volume CleanCap [27][30] - Strategic investments include expanding commercial footprint and intellectual property protection while managing costs [31][45] - Recent acquisitions are expected to enhance capabilities in DNA and RNA design and discovery, positioning the company for future growth [48][62] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in forecasting due to market dynamics but expressed confidence in the company's assets and growth potential [25][26] - The company is enhancing visibility into customer clinical programs to improve sales forecasting accuracy [42][53] Other Important Information - The company ended 2024 with $322 million in cash and $300 million in long-term debt, resulting in a net cash position of $22 million [18][19] - Capital expenditures for 2024 were $30 million, with expectations for a decline to $15 million to $20 million in 2025 [20][33] Q&A Session Summary Question: Can you provide insights on profitability and gross margins for 2025? - Management indicated that the cost structure for 2025 will remain consistent with 2024, with fixed costs around $200 million and variable costs ranging between 10% and 12% [66][68] Question: How is the company improving visibility with key customers? - Management noted that new agreements include mandatory disclosure requirements for clinical trial milestones, which should enhance visibility [75][77] Question: What are the expectations for segment growth and market assumptions? - Management expects Q1 revenues to be slightly up from Q4 2024, with growth driven by GMP programs and the integration of recent acquisitions [80][83] Question: What are the capital allocation priorities for 2025? - The company plans to focus on reducing cash interest expenses and is open to M&A opportunities that align with their strategic goals [88][90] Question: How does the company view its exposure to NIH funding changes and growth in China? - Management does not anticipate significant headwinds from NIH funding changes and expects flat growth in China for 2025 [97][100]